Clinical Trial

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well tailored prednisone reduction works in preventing hyperglycemia in participants with B-cell non-Hodgkin lymphoma receiving combination chemotherapy treatment. Drugs used in chemotherapy, such as rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Reductions in prednisone dose may lower blood sugar levels.
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-08-12
minor Completion pushed: 2025-11 -> 2029-06 2026-08-12
Trial Details
NCT Number NCT03505762
Lead Sponsor Wake Forest University Health Sciences
Collaborators: National Cancer Institute (NCI)
Conditions B-Cell Non-Hodgkin Lymphoma
Enrollment 80 participants
Start Date 2018-07-19
Primary Completion 2024-03-28 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-11